Nusayba Bagegni is an Oncology physician affiliated with Washington University in St. Louis. OpenAlex indexes 113 publications with 709 citations (h-index 14); ClinicalTrials.gov lists 4 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1 Barnes Jewish Hospital Plz
Div Im Medical Oncology
Saint Louis, MO 631101003
Telephone
314-747-1171Registry record last updated 12 May 2026.
Clinical trials
- Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis
Sponsor: Washington University School of Medicine
- BettER: Biomarker Driven Early Therapeutic Selection in Patients With HR+ HER2- Metastatic or Unresectable Breast Cancer
Sponsor: Washington University School of Medicine
- NeoTAILOR: ABiomarker-directed Approach to Guide Neoadjuvant Therapy for Patients With Stage II/III ER-positive, HER2-negative Breast Cancer
Sponsor: Washington University School of Medicine
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Gilead Sciences, Inc.Program year20211 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
47.9%Aromatase Inhibitor33.3%Anastrozole60%Letrozole32%Exemestane8%Part D≥85 patientsKinase inhibitor7.8%Ibrance83%Tukysa9%Kisqali9%Part D<11 patients+ 4 more classes in this area
Sensory organs
21.2%Corticosteroid21.2%Dexamethasone sodium phosphate86%Dexamethasone11%Hydrocortisone4%Part D + Part B<11 patientsMetabolism & gastrointestinal
17.8%Serotonin-3 Receptor Antagonist13.2%Palonosetron hcl77%Ondansetron Hcl17%Ondansetron Odt6%Part D + Part B<11 patientsOpioid Agonist1.2%Loperamide100%Part D<11 patients+ 4 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Long-Term Results of a Phase 2 Prospective Clinical Trial of Single-Fraction, High-Gradient Adjuvant Partial Breast Irradiation in Early-Stage, Hormone-Positive Breast Cancer
International Journal of Radiation Oncology*Biology*Physics
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Randall Bateman, MD
Washington University in St. Louis
Janet McGill, MD
Washington University in St. Louis
Robert Carney, MD
Washington University in St. Louis
David Clifford, MD
Washington University in St. Louis
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Larry Norton, MD
Memorial Sloan Kettering Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”